Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease | MicrobiomeTrials← Back to trialsNCT07566494
Escalating Doses of VAS-101 in Subjects With Stable Sickle Cell Disease
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-07-30Est. Completion: 2027-04-27
Enrollment target: 25 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
Sickle Cell DiseasePulmonary DiseaseRenal DiseaseHeart Disease
Sickle Cell Disease is one of the most common genetic diseases in the United States, occurring in approximately 1 in 400…
Washington D.C., United StatesEst. completion Nov 2026
Sickle Cell Disease
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibro…
Los Angeles, United StatesEst. completion Dec 2026